Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients

Leukemia

Volumn 30, Issue 1, 2016, Pages 112-123

  Jilg, S ^a   Reidel, V ^a   Muller Thomas C ^a   Konig J ^a   Schauwecker, J ^a   Hockendorf U ^a   Huberle, C ^a   Gorka, O ^a   Schmidt, B ^b   Burgkart, R ^a   Ruland, J ^a   Kolb, H J ^a   Peschel, C ^a   Oostendorp, R A J ^a   Gotze K S ^a   Jost, P J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Gemeinschaftspraxis Hämato Onkologie Pasing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; CD34 ANTIGEN; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; VENETOCLAX; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; ABT-737; BIPHENYL DERIVATIVE; FUSED HETEROCYCLIC RINGS; MCL1 PROTEIN, HUMAN; NITROPHENOL; PIPERAZINE DERIVATIVE; SULFONAMIDE;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DEATH; CELL DIFFERENTIATION; CELL SUBPOPULATION; CELL SURVIVAL; COHORT ANALYSIS; COLONY FORMING CELL; CONTROLLED STUDY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA WITH EXCESS BLASTS; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; STEM CELL;

APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIPHENYL COMPOUNDS; CELLS, CULTURED; HUMANS; MYELODYSPLASTIC SYNDROMES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; STEM CELLS; SULFONAMIDES;

EID: 84953360082     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.179     Document Type: Article

References (59)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-1885.
2. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007; 7: 118-129.
3. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012; 12: 849-859.
4. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109: 1536-1542.
5. Shetty V, Hussaini S, Broady-Robinson L, Allampallam K, Mundle S, Borok R et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 2000; 96: 1388-1392.
6. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268-276.
7. Raza A, Alvi S, Broady-Robinson L, Showel M, Cartlidge J, Mundle SD et al. Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo-and/or bromodeoxyuridine. Exp Hematol 1997; 25: 530-535.
8. Parker JE, Mufti GJ. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 1998; 101: 220-230.
9. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 3932-3938.
10. Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjian HM et al. Myelodysplastic syndrome is not merely 'preleukemia'. Blood 2002; 100: 791-798.
11. Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 1997; 11: 656-659.
12. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
13. Invernizzi R, Pecci A, Bellotti L, Ascari E. Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes. Leuk Lymphoma 2001; 42: 481-489.
14. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 2011; 30: 3667-3683.
15. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337.
16. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37: 299-310.
17. Pop C, Salvesen GS. Human caspases: activation, specificity, and regulation. J Biol Chem 2009; 284: 21777-21781.
18. Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell 2013; 23: 139-141.
19. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
20. Letai A. BCL-2: found bound and drugged!. Trends Mol Med 2005; 11: 442-444.
21. Cragg MS, Harris C, Strasser A, Scott CL. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 2009; 9: 321-326.
22. Khaw SL, Huang DC, Roberts AW. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. Pathology 2011; 43: 525-535.
23. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
24. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488-496.
25. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
26. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G et al. Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. Cancer Discov 2014; 4: 362-375.
27. Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 2014; 28: 1657-1665.
28. Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820-829.
29. Oostendorp RA, Medvinsky AJ, Kusadasi N, Nakayama N, Harvey K, Orelio C et al. Embryonal subregion-derived stromal cell lines from novel temperature-sensitive SV40 T antigen transgenic mice support hematopoiesis. J Cell Sci 2002; 115: 2099-2108.
30. Oostendorp RA, Robin C, Steinhoff C, Marz S, Brauer R, Nuber UA et al. Long-term maintenance of hematopoietic stem cells does not require contact with embryo-derived stromal cells in cocultures. Stem Cells 2005; 23: 842-851.
31. Ledran MH, Krassowska A, Armstrong L, Dimmick I, Renstrom J, Lang R et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 2008; 3: 85-98.
32. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010; 28: 2529-2537.
33. Zekavati A, Nasir A, Alcaraz A, Aldrovandi M, Marsh P, Norton JD et al. Post-transcriptional regulation of BCL2 mRNA by the RNA-binding protein ZFP36L1 in malignant B cells. PLoS One 2014; 9: e102625.
34. Kutuk O, Letai A. Regulation of Bcl-2 family proteins by posttranslational modifications. Curr Mol Med 2008; 8: 102-118.
35. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001; 15: 515-522.
36. Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 2010; 184: 16-20.
37. Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011; 96: 1433-1440.
38. Woll PS, Kjallquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 2014; 25: 794-808.
39. Pang WW, Pluvinage JV, Price EA, Sridhar K, Arber DA, Greenberg PL et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci USA 2013; 110: 3011-3016.
40. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-388.
41. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334: 1129-1133.
42. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012; 151: 344-355.
43. Jaiswal S, Ebert BL. MDS is a stem cell disorder after all. Cancer Cell 2014; 25: 713-714.
44. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-841.
45. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-846.
46. Raaijmakers MH, Scadden DT. Evolving concepts on the microenvironmental niche for hematopoietic stem cells. Curr Opin Hematol 2008; 15: 301-306.
47. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6: 93-106.
48. Scadden DT. The stem-cell niche as an entity of action. Nature 2006; 441: 1075-1079.
49. Li X, Deeg HJ. Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells. Exp Hematol 2014; 42: 4-10.
50. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852-857.
51. Kusadasi N, Oostendorp RA, Koevoet WJ, Dzierzak EA, Ploemacher RE. Stromal cells from murine embryonic aorta-gonad-mesonephros region, liver and gut mesentery expand human umbilical cord blood-derived CAFC(week6) in extended long-term cultures. Leukemia 2002; 16: 1782-1790.
52. Oostendorp RA, Harvey KN, Kusadasi N, de Bruijn MF, Saris C, Ploemacher RE et al. Stromal cell lines from mouse aorta-gonads-mesonephros subregions are potent supporters of hematopoietic stem cell activity. Blood 2002; 99: 1183-1189.
53. Parmar A, Marz S, Rushton S, Holzwarth C, Lind K, Kayser S et al. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors. Cancer Res 2011; 71: 4696-4706.
54. Omidvar N, Kogan S, Beurlet S, le Pogam C, Janin A, West R et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res 2007; 67: 11657-11667.
55. Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N et al. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood 2013; 122: 2864-2876.
56. Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis 2015; 6: e1593.
57. Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H et al. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia 2012; 26: 788-794.
58. Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 2012; 26: 778-787.
59. Muller-Thomas C, Rudelius M, Rondak IC, Haferlach T, Schanz J, Huberle C et al. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica 2014; 99: e179-e181.